Therapy Areas: Respiratory
Sophos IRB and ALCMI partner to support lung cancer research
9 October 2026 - Sophos IRB Inc, an independent, oncology-focused central institutional review board, announced on Thursday a strategic partnership with the Addario Lung Cancer Medical Institute (ALCM...
CSL and Alentis partner for lixudebart development and commercialisation for rare kidney and liver diseases
5 October 2026 - Australian biopharma company CSL Limited (ASX:CSL) (USOTC:CSLLY) and Swiss biotechnology company Alentis Therapeutics announced on Sunday that they have entered into an exclusive glob...
MHRA approves Zepzelca and atezolizumab as first-line maintenance therapy for ES-SCLC in the UK
1 October 2026 - Swedish pharmaceutical company Immedica Pharma AB, backed by investment firms KKR & Co. Inc. (NYSE: KKR) and Impilo, announced on Thursday that its partner, Spanish biopharmaceuti...
UTR Therapeutics' UTRxMYCN M1-14 receives US FDA Orphan Drug Designation and Rare Pediatric Disease Designation
30 September 2026 - UTR Therapeutics Inc, a New York-based biotech company, announced on Tuesday that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to 3'UTRMYCN M1...
AstraZeneca invests USD2bn in Summit Therapeutics to advance ADC and cancer-drug combinations
29 September 2026 - Biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN) announced on Tuesday that it has agreed to invest USD2bn in newly issued equity in biopharmaceutical oncolo...
QIAGEN completes US QIAstat-Dx bloodstream infection portfolio with FDA clearance
28 September 2026 - Netherlands-based holding company QIAGEN N.V. (NYSE:QGEN) (Frankfurt Prime Standard:QIA) announced on Monday that it has received US Food and Drug Administration (FDA) clearance fo...